Scientific publications are a fundamental part of communicating CareMiBrain’s advances in the diagnosis of neurological diseases to the medical community.
If you are interested in the complete list of published or submitted articles, posters and presentations up to date please contact to Oncovision’s Medical Director Gabriel G.Pavón here.
Numbers of people with dementia
1 in 6 people worldwide will suffer from a neurological disease. 60% of them are women. Currently more than 55 million people have dementia worldwide and every year, there are nearly 10 million new cases.
In 2019, dementia cost economies globally 1.3 trillion US dollars and is expected to rise to US$ 2.8 trillion by 2030.
Research shows that most people currently living with dementia have not received a formal diagnosis. The statistics suggests that approximately three quarters of people with dementia have not received a diagnosis, and therefore do not have access to treatment, care and organised support that getting a formal diagnosis can provide.
Earlier diagnosis and early intervention are important mechanisms by which the treatment gap can be closed.
Alzheimer’s disease begins 20 years or more before the onset of symptoms suggests that there is a substantial window of time in which we may be able to intervene in the progression of the disease.
Scientific advances are already helping this field as the identification of biomarkers for Alzheimer’s making possible to identify individuals who have beta-amyloid accumulation in the brain and who may qualify for clinical trials of experimental treatments that aim to reduce the accumulated beta-amyloid and in so doing prevent or delay the onset of symptoms.
Biomarkers and Medical Imaging as CareMiBrain enable earlier detection of Alzheimer’s, giving those affected the opportunity to address modifiable risk factors that may slow or delay cognitive decline.
Gabriel G. Pavón
Calle Jerónimo de Monsoriu, 92 bajo izq. 46022 Valencia (Spain)